Testicular Growth and Pubertal Onset in GH-Deficient Children Treated With Growth Hormone: A Retrospective Study

Front Endocrinol (Lausanne). 2021 Apr 2:12:619895. doi: 10.3389/fendo.2021.619895. eCollection 2021.

Abstract

The prevalence of idiopathic oligozoospermia has been esteemed as high as 75%. An Italian survey has reported bilateral testicular hypotrophy in 14% of final-year high school students. The search for determinants of testicular growth in childhood is important for the primary prevention of spermatogenic failure. Therefore, this retrospective study aimed to evaluate the testicular growth and pubertal onset in deficient children treated recombinant human growth hormone (rhGH). To accomplish this, the clinical charts of 93 patients with GH deficiency (GHD) were carefully reviewed. Their mean age at the time of diagnosis was 11.2 ± 2.4 years. rhGH was administered for 44.0 ± 22.4 months, and the onset of puberty was recorded after a mean of 25.8 ± 22.4 months from the first rhGH administration. As expected, serum insulin-like growth factor 1 (IGF1) levels increased significantly after treatment. Before rhGH therapy, the Tanner stage was I in 59 out of 70 boys (84.3%), II in 8/70 (11.4%), III in 3/70 (4.3%). No one was on stage IV or V. The mean Tanner stage was 1.19 ± 0.51. At the last visit, the Tanner stage was I in 8/72 boys (11.1%), II in 6/72 (8.3%), III in 6/72 (8.3%), IV in 16/72 (22.2%), and V in 36/72 (50.0%). After a mean of 44.0 ± 22.4 months of rhGH treatment, the mean Tanner stage was 4.05 ± 1.30. Patients treated with rhGH showed a significant testicular volume (TV) growth over time, whereas no growth was observed in age-matched but not yet treated patients, even when the age was compatible with a spontaneous start of puberty. The multivariate regression analysis showed that the duration of treatment and the mean rhGH dose significantly predicted the percentage of TV increase. In contrast, age, serum FSH, and IGF1 levels, and final rhGH dose did not impact TV growth over time. In conclusion, these findings suggest that GH may play a role in testicular growth and pubertal onset, despite the descriptive nature of this study. Further properly designed studies are needed to confirm these findings. This knowledge may be useful to implement the diagnostic-therapeutic algorithm in case of a lack of testicular growth in childhood.

Keywords: GH deficiency; GHD; IGF1; infertility; oligozoospermia; testicular growth; testicular volume.

MeSH terms

  • Adolescent
  • Child
  • Growth Disorders / blood
  • Growth Disorders / drug therapy*
  • Hormone Replacement Therapy*
  • Human Growth Hormone / administration & dosage
  • Human Growth Hormone / deficiency
  • Human Growth Hormone / therapeutic use*
  • Humans
  • Insulin-Like Growth Factor I / metabolism
  • Male
  • Puberty / drug effects*
  • Recombinant Proteins / administration & dosage
  • Recombinant Proteins / therapeutic use*
  • Retrospective Studies
  • Testis / drug effects
  • Testis / growth & development*

Substances

  • IGF1 protein, human
  • Recombinant Proteins
  • Human Growth Hormone
  • Insulin-Like Growth Factor I